Overview of Recent Updates in Bispecific Therapy in R/R MM

Opinion
Video

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

  • Discuss similarities/differences in mechanism of action, key efficacy endpoints and safety data:
  • Teclistamab 
  • MajesTEC-1 (NEJM 2022)
  • MajesTEC-1 Long-term Follow-up (ASCO 2024)
Recent Videos
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Related Content
The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

Roman Fabbricatore
October 13th 2025
Article

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.

Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

Tim Cortese
October 1st 2025
Article

D-VRd had a 72% chance of providing superior PFS outcomes vs isatuximab plus VRd in patients with transplant-ineligible NDMM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.

Dara-KRd Regimen Displays Prolonged PFS in Newly Diagnosed Multiple Myeloma

Roman Fabbricatore
September 22nd 2025
Article

The median PFS was not reached with daratumumab-lenalidomide maintenance after a median follow-up of 49 months in those with multiple myeloma.